A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

Publication | Open Access

DOI Full Paper Access

Citations

References

2012

Year

Klaus Baumann, Andreas du Bois, Werner Meier, Jörn Rau, Pauline Wimberger, Jalid Sehouli, Christian Kurzeder, Felix Hilpert, Annette Hasenburg, Ulrich Canzler,

Annals of Oncology

Ago 2.11MedicinePharmacologyClinical TrialsGynecologyPharmacotherapyAnti-cancer AgentRandomized Multicenter TrialPlatinum-resistant Ovarian CancerCancer TreatmentOncologyOvarian Cancer